Aldevron Breakthrough Blog

Apply for the Nanoplasmidᵀᴹ AAV Construct Giveaway

Overcoming challenges, increasing yields

In efforts to bring the next-generation of plasmid technology to the cell and gene therapy space, Aldevron is offering a giveaway to customers developing AAV based therapies. Nanoplasmid benefits in the context of AAV include improved ITR stabilization from its proprietary host strain while increasing plasmid yields compared to conventional plasmid vectors. 

Typical host strains exhibit difficulty in producing plasmids with structural DNA or palindromic sequences, but Nanoplasmid’s host strain was designed to overcome these challenges while improving plasmid yield simultaneously. 

Nanoplasmid is a next-generation plasmid technology designed to address the rigors of safety and performance required in the cell and gene therapy (CGT) space. Conventional plasmids were not initially created to be used in the CGT space with their large and antiquated backbones containing bacterial coding regions and antibiotic resistance genes. 

Nanoplasmid overcomes these challenges with its antibiotic-free selection system and its R6K strain dependency, greatly reducing the risk of horizontal gene transfer and further adding to its safety profile.

Giveaway applicants will be awarded a free retrofit of an ITR bearing construct and a discount on retrofitting their helper or rep/cap plasmids used in the manufacturing of AAV. Interested applicants should visit our page and fill out our five-question application, including uploading an optional abstract describing the AAV project.

About the author

Latest posts

Patrick Paez, Ph.D.

Patrick Paez, Ph.D.

Patrick Paez serves as a technical marketing manager for Aldevron’s marketing team. He earned a bachelor's degree in Pre-Medicine and Psychology, and a Ph.D. in Immunology at Virginia Commonwealth University (VCU) in Richmond, VA. His Ph.D. training at VCU's Medical College of Virginia campus was in a translational science lab at the Massey Cancer Center, where he focused on developing immunotherapeutic interventions in the field of immuno-oncology for phase 1 clinical trials.

Topics: Plasmid DNA, Nanoplasmid